Abstract A 75 year old female presented with a sellar tumour, and was subsequently found also to have a cauda equina tumour, a parietal dural tumour, a pontine tumour, an intradural spinal tumour, and several vertebral body tumours. Histological examination revealed a neuroendocrine tumour forming cell nests surrounded by reticulin. There was moderate nuclear pleomorphism, prominent mitoses, and focal necrosis. Immunohistochemistry showed diffuse positive staining with cytokeratins, chromogranin and 5-hydroxytryptamine, and focal positive staining with S 100. This case is an unusual and ultimately insoluble, diagnostic problem; however, the differential diagnoses include pituitary carcinoma, malignant paraganglioma, and atypical carcinoid. (7 Clin Pathol 1997;50:440-442) Keywords: neuroendocrine malignancy; carcinoid; paraganglioma The histopathological examination of neuroendocrine tumours poses particular diagnostic problems for several reasons. One of the most frustrating of these is that the histological appearances do not correlate well with behaviour: metastasis from tumours with a bland cytological appearance is well documented, and tumours showing nuclear atypia may not behave in a malignant fashion. While neuroendocrine differentiation may be evident on light microscopy in some cases, in others immunocytochemistry or electron microscopy may be required. Another problem is that neuroendocrine tumours arise from a wide variety of sites ranging from organoid collections of endocrine and neural cells to a diffuse and scattered neuroendocrine cell population present within many organ systems. The nomenclature of neuroendocrine tumours is consequently confusing as, for historical reasons, different names have been given to tumours that are histologically similar, but have arisen in different sites. In contrast the same name is often applied to tumours with a widely differing prognosis. Histopathological classification of metastatic neuroendocrine tumours is therefore extremely difficult if the primary site is not known or if multiple possibilities are present.
The histopathological examination of neuroendocrine tumours poses particular diagnostic problems for several reasons. One of the most frustrating of these is that the histological appearances do not correlate well with behaviour: metastasis from tumours with a bland cytological appearance is well documented, and tumours showing nuclear atypia may not behave in a malignant fashion. While neuroendocrine differentiation may be evident on light microscopy in some cases, in others immunocytochemistry or electron microscopy may be required. Another problem is that neuroendocrine tumours arise from a wide variety of sites ranging from organoid collections of endocrine and neural cells to a diffuse and scattered neu- roendocrine cell population present within many organ systems. The nomenclature of neuroendocrine tumours is consequently confusing as, for historical reasons, different names have been given to tumours that are histologically similar, but have arisen in different sites. In contrast the same name is often applied to tumours with a widely differing prognosis. Histopathological classification of metastatic neuroendocrine tumours is therefore extremely difficult if the primary site is not known or if multiple possibilities are present.
We present the results of histological and immunohistochemical examination of a neuroendocrine tumour present at five sites within the central nervous system: sella turcica, pons, cauda equina, spinal intradural, and parietal falx, together with multiple foci within vertebral bodies. All these tumours presented within months of each other, thus obscuring which, if any, was the primary site.
Case report A 75 year old female first presented in June 1995 with symptoms and signs of hypopituitarism, together with a deterioration in visual acuity. Computed tomography (CT) revealed a lesion arising from the pituitary fossa with suprasellar extension. The appearances were consistent with a pituitary adenoma and she was treated with replacement therapy; however, no surgical procedure was undertaken at that time.
In October 1995 the patient presented with an exacerbation of lower back pain of one year's duration. A two day history of urinary retention was elicited. Examination revealed decreased sensation within dermatomes L3, L4, and L5, together with absent ankle and knee reflexes bilaterally. CT myelography revealed an intradural lesion at the level of L3-L4. This was surgically decompressed, and tissue removed for histology.
Postoperative recovery of function was good, however, her visual acuity continued to deteriorate. Ophthalmological examination suggested a bitemporal defect, probably produced by the chiasmal lesion. Magnetic resonance imaging (MRI) confirmed the previously identified sellar lesion, but also detected a central pontine lesion, a lesion apparently arising from the parietal falx, and a smaller, equivocal dural lesion nearby. In addition, an MRI of the cervical and thoracic spine showed a rounded intradural tumour at the level of TI and vertebral body tumours at T5, T7, and T8. A right pteryonal craniotomy and debulking of the chiasmatic tumour was performed and tissue was submitted for histology. The histological appearances were similar to that of the cauda equina tumour.
There was no improvement in visual acuity and further treatment was felt to be inappropriate because of the presence of widespread tumour. Of note was a complete absence of any symptoms related to other organ systems. Hormone assays were also consistently negative and there was no relevant past medical or family history. There was diffuse immunoreactivity of tumour cells with cytokeratin markers (CAM 5.2 (Becton Dickinson, UK) and MNF 116 (Dako, Denmark)) and neuroendocrine markers neuron specific enolase (NSE, Dako), NCAM (Serotec Ltd, UK), chromogranin A (Dako), and focal positive staining with anti-5-hydroxytryptamine (Dako). Focal positivity for Si00 was also seen within the tumour, but appeared to correspond to sustentacular cells, in that the S100 positive cells were situated predominantly at the edges of the cell nests ( fig  2) . Staining for carcinoembryonic antigen (CEA, Dako), glial fibrillary acidic protein (Dako), human melanoma clone B45 (Dako, USA), and pituitary secretory hormones (adrenocorticotrophic hormone, alpha subunit, thyroid stimulating hormone, follicle stimulating hormone, growth hormone, luteinising hormone, alpha human chorionic gonadotrophin, and prolactin) was negative.
As both biopsy specimens were small, no residual tissue was available for de novo electron microscopy.
Discussion
The presence of widespread tumour precluded a diagnosis on the basis of primary site. The tumours were neuroendocrine in nature, with features that increased the likelihood of malignant behaviour. Several differential diagnoses were considered: an atypical carcinoid of unknown primary site, a malignant paraganglioma, and a pituitary carcinoma. This fascinating case posed an ultimately insoluble diagnostic conundrum, and to our knowledge no such case has been reported previously.
Neuroendocrine tumours of the diffuse endocrine system, particularly those of the lung and gastrointestinal tract, have traditionally been referred to as carcinoid tumours. Their -s . . 
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malignant potential, by virtue of size and cytology, being termed atypical carcinoids. In addition to positive staining with routine epithelial and neuroendocrine markers, they usually express CEA but not S100. Although commonly presenting as a primary lesion, metastases are not unusual and silent primary tumours have been described.' Neurological complications are present in 40% of metastatic carcinoids and true central nervous system metastases have been documented both within the brain and spinal cord. 2 Primary paragangliomas of the cauda equina are well described' and, although malignant behaviour is rare, metastatic spread has been documented.4 Nuclear atypia and necrosis are unusual features. Positive staining for cytokeratin is uncommon and has not been reported for CEA to our knowledge. The supporting sustentacular cells are classically S 100 pcsitive, although they are not always present. 5 Pituitary carcinomas are a well recognised albeit rare entity. Generalised spread has been reported6 although central nervous system spread is more common. Metastasis to the cauda equina has been documented.7 Most carcinomas are histologically identical to adenomas; however, nuclear atypia has been recorded and said to indicate increased malignant potential.8 Cytokeratin positivity has been reported9 but is uncommon; however, the pituitary is a relatively common site for metastatic carcinoma from other sites.'0 Conclusion This widespread tumour illustrates the problem of classifying neuroendocrine tumours when there is no obvious primary site. The diagnoses of atypical carcinoid, malignant paraganglioma, and pituitary carcinoma were all considered; however, our favoured diagnosis was atypical carcinoid. 
